RMA of New York offers PGS (Preimplantation Genetic Screening) in conjunction with PGD (Preimplantation Genetic Diagnosis) to test embryos for chromosomal anomalies (aneuploidy) prior to transferring them to the uterus. Where PGD is the term used to diagnose a genetic defect by analyzing the cells of an embryo, PGS refers to the testing and screening for potential chromosomal deficiencies. Couples facing factors such as advanced maternal age (over 35), a history of failed IVF cycles or recurrent miscarriages, or a family history of genetic disorders may have an increased chance of developing a chromosomally abnormal embryo. Recent research studies have found that PGS may significantly improve the chances for couples to have a healthy and successful pregnancy by selecting and transferring only chromosomally normal embryos.
Recent scientific data demonstrates that more than 50% of embryos created may turn out to be chromosomally abnormal and nearly half of embryos that implant may still miscarry. The profound discoveries resulting from utilization of genetic technologies such as PGS/PGD have illustrated just how considerable the risks for developing nonviable pregnancies on IVF patients can be, and in turn are reshaping the future of reproductive science. Since conception of a nonviable pregnancy and resultant miscarriage can result in the loss of up to six months before the next attempt for IVF can occur, the transfer of normal embryos is a priority. There is also tremendous emotional cost to couples who undergo miscarriage. Though genetic analysis of embryos has been performed for two decades, recent advances have enabled biopsy and analysis of advanced (blastocyst) embryos on day 5 of culture. An analysis of just two to three cells of the 100 cells present at that stage provides a sufficient amount of material for Comprehensive Chromosomal Screening (CCS). Rather than biopsying the polar body which can be unreliable, or the Day 3 cleavage stage embryo which can compromise embryo viability, we have found that biopsy of the trophectoderm when the embryos are comprised of 100-cells can offer meaningful information without compromising the viability of the embryo.
The benefits of these advanced procedures are expected to prove further encouraging results by preventing the devastating effects of failed IVF cycles and miscarriages, and improving the ability to successfully screen for inherent diseases including cystic fibrosis, Tay Sachs, sickle cell anemia, as well as Down syndrome. As our goal is to offer the most effective treatment for couples on an individualized basis, by utilizing these scientific breakthroughs we are able to transfer the most viable embryo to achieve a healthy ongoing pregnancy.
How Is IUI Done? Here’s The Step-By-Step Of What To Expect View the Article here. ...READ MORE
When is the Right Time to See a Fertility Specialist? By: Daniel Stein, MD, RMA of NY It is estimated that approximately one of every eight couples (12%-13%) suffers from infertility, a disease defined as the failure to conceive after twelve months in women 35 or younger, or after six ...READ MORE
January 30th, 2018 – RMA of New York & Glow – IVF Event RMA of New York & Glow – IVF Event Featuring Dr Beth McAvey Tuesday, January 30th, 2018 2 West 46th Street, Suite 1404, New York, NY 10036 6:30 – 8:30 pm RSVP on Eventbrite ...READ MORE
February 1st, 2018 – RMA of New York & Glow – IVF Event Thursday, February 1st, 2018 ...READ MORE
to receive all the latest News, Events & MORE!